Why the study?
Does an aggressive multimodality approach improve survival in patients with metastatic osteosarcoma?
Does an aggressive multimodality approach improve survival in patients with metastatic osteosarcoma?
An aggressive multimodality approach yielded a median survival of 12+ months in a small cohort of patients with metastatic osteosarcoma.
May support multimodality therapy in select metastatic osteosarcoma cases; hypothesis-generating and requires prospective validation.
Ten patients with metastatic osteosarcoma were treated at the Joint Center for Radiation Therapy, the Sidney Farber Cancer Institute, and the Children's Hospital Medical Center from 1973 to 1976. Patients were treated with an aggressive multimodality approach with included surgery, chemotherapy, and radiation therapy. Three of 10 patients are alive with no evidence of disease, five are alive, with disease, and two are dead of disease. The median survival is 12+ months. Local control data for radiation combined with high dose methotrexate in metastatic osteosarcoma is shown.
No takes yet. Share an insight, caveat, or question.
Weichselbaum et al. (1977) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: